International: +1-347-960-6455
Shigella Infection (Shigellosis) Therapeutics - Pipeline Analysis 2018

Shigella Infection (Shigellosis) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10072 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Infectious
Select License Type

Shigella infection, also known as shigellosis, is a bacterial infection caused by a family of bacteria known as shigella. The main symptom of this infection is diarrhea, and can be passed through direct contact with the bacteria in the stool. The other sign and symptoms associated with shigella infection are abdominal pain, cramps, and fever. Children between the age of two and four years are more prone to develop shigella infection. According to the data published by the Centers for Disease Control and Prevention, every year, there are about 500,000 cases of shigellosis in the U.S. Antibiotics and fluid and salt replacement are the standard treatment strategies for shigella infection. LimmaTech Biologics is in the process of developing shigella vaccine as a conjugate for the treatment of shigella diarrhea prophylaxis. Other than this Protein Potential LLC is also engaged in developing drug candidates for this infection.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.